Postherpetic neuralgia is treated with a combination of topical pain relievers, oral medications that calm overactive nerves, and sometimes interventional procedures, though no single therapy eliminates the pain for everyone. PHN develops after a shingles outbreak when damaged nerve fibers keep firing pain signals long after the rash has healed, and the condition can persist for months or years. Treatment typically starts with topical lidocaine or capsaicin patches and oral gabapentinoids or antidepressants, then escalates to stronger options if pain remains stubborn.
First-Line Topical Treatments
Topical therapies are often where treatment begins, partly because they deliver medication directly to the painful area and carry very little risk of the systemic side effects that oral drugs can cause. For many people with PHN, the pain is concentrated in a well-defined patch of skin, making a localized approach practical.
The lidocaine 5% patch is one of the most widely recommended starting points. It numbs the skin surface by blocking sodium channels in pain-signaling nerve fibers. Clinical trials have shown it reduces both ongoing pain and the touch-triggered pain (allodynia) that makes even clothing against the skin unbearable for some PHN patients. Systemic absorption of lidocaine from the patch is minimal, and side effects are mostly limited to mild skin reactions at the application site, making it safe for long-term use and in older adults.1PubMed. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia A placebo-controlled trial in Chinese patients confirmed that lidocaine patches produced significantly greater pain relief than placebo by week four, with no meaningful difference in adverse event rates between the two groups.2PubMed Central. Randomized, Placebo-Controlled, Multicenter Clinical Study on the Efficacy and Safety of Lidocaine Patches in Chinese Patients with Postherpetic Neuralgia
The other major topical option is the high-concentration capsaicin 8% patch, sold under the brand name Qutenza. Capsaicin is the compound that makes chili peppers hot, and at high concentrations it overwhelms and then desensitizes the pain-sensing nerve endings in the skin. The initial application causes intense burning and redness, which is why it is applied in a clinic setting for 60 minutes rather than at home. After that single treatment, pain relief can last up to 12 weeks before another application is needed.3PubMed. Qutenza®: a capsaicin 8% patch for the management of postherpetic neuralgia The patch has been approved for PHN in both the United States and Europe, and trials consistently show rapid, sustained pain relief from a single session.4PubMed. Capsaicin 8% Dermal Patch: A Review in Peripheral Neuropathic Pain The trade-off is that the application itself is uncomfortable, and some people find the burning intolerable even for the required hour.
First-Line Oral Medications
When topical treatments alone are not enough, or when the pain covers a large area, oral medications become the backbone of PHN management. Three drug classes dominate the first-line oral options: gabapentinoids, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors (SNRIs). None of these were originally designed as painkillers, but all have strong evidence for dampening neuropathic pain.
Gabapentin and Pregabalin
Gabapentin and pregabalin belong to a class informally called gabapentinoids. They work by binding to calcium channels on nerve cells, which reduces the release of excitatory chemical signals and quiets the overactive pain pathways that drive PHN. Both drugs also improve sleep, which is a meaningful benefit since PHN frequently disrupts it.5PubMed Central. Treatment of postherpetic neuralgia: focus on pregabalin
A meta-analysis comparing the two found that pregabalin was somewhat better at reducing pain and improving patients’ overall perception of improvement, but gabapentin had a lower rate of side effects.6PubMed Central. A Meta-analysis of Randomized Controlled Trials Comparing the Efficacy and Safety of Pregabalin and Gabapentin in the Treatment of Postherpetic Neuralgia The most common side effects for both include dizziness, drowsiness, and swelling of the hands or feet. One small study suggested that pregabalin was roughly six times more potent than gabapentin on a milligram-for-milligram basis, but cautioned that this increased potency also means side effects can escalate faster if the dose is raised too quickly.7PubMed. Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy In practice, doctors often start with gabapentin because it is cheaper and better tolerated, then switch to pregabalin if the response is inadequate.
Tricyclic Antidepressants and SNRIs
Tricyclic antidepressants such as amitriptyline and nortriptyline have decades of use in neuropathic pain. They work by increasing the activity of norepinephrine and serotonin in the spinal cord’s pain-modulating pathways, essentially turning up the volume on the body’s built-in pain-suppression system. A case series of four patients who had failed multiple other treatments, including lidocaine patches, gabapentinoids, and opioids, found that adding a tricyclic antidepressant led to meaningful reductions in pain intensity with minimal side effects (mild sedation and dry mouth in two patients).8PubMed Central. The Use of Tricyclic Antidepressants for Postherpetic Neuralgia – A Case Series The catch is that tricyclics can cause heart rhythm changes, urinary retention, and confusion, which makes them trickier to use in older patients.
Duloxetine, an SNRI, offers a similar mechanism with a somewhat cleaner side-effect profile. A randomized crossover trial compared duloxetine combined with pregabalin against amitriptyline combined with pregabalin in PHN patients. Both combinations significantly reduced pain from baseline, with good pain relief reported by about half of patients in each group and no statistically significant difference between them.9PubMed Central. Comparison of Duloxetine Supplemented With Pregabalin and Amitriptyline Supplemented With Pregabalin for the Treatment of Postherpetic Neuralgia This gives clinicians a useful alternative when a tricyclic’s side effects are a concern.
When First-Line Treatments Are Not Enough
A frustrating reality of PHN is that first-line medications, even in combination, leave a substantial number of patients still in moderate-to-severe pain. Clinical guidelines from the Korean Pain Society recommend adding tramadol for patients whose pain remains at or above a 4 out of 10 after at least a month on first-line agents.10Korean Journal of Pain. Clinical practice guidelines for the management of refractory postherpetic neuralgia by the Korean Pain Society A randomized trial found tramadol significantly reduced pain intensity compared to placebo over six weeks, with a side-effect profile similar to placebo.11PubMed. Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial
Across neuropathic pain conditions including PHN, the estimated number of patients you need to treat with tramadol for one person to achieve at least 50% pain relief is about five, which is actually better than the corresponding figure for gabapentin or pregabalin alone.10Korean Journal of Pain. Clinical practice guidelines for the management of refractory postherpetic neuralgia by the Korean Pain Society Strong opioids like oxycodone are a further step, reserved for patients who still have uncontrolled pain despite tramadol and first-line drugs. One study found that oxycodone reduced average pain scores from about 7.4 to 1.4 over eight weeks, but the evidence supporting strong opioids in PHN is rated very low in quality, and the risks of nausea, constipation, dependence, and addiction mean they should not be the first resort.
Interventional Procedures
For patients whose pain does not respond adequately to medications, several procedural options exist. These tend to be performed by pain specialists and vary widely in how invasive they are.
Epidural steroid injections deliver anti-inflammatory medication directly into the space around the spinal cord. A Mayo Clinic review found that patients who experienced moderate-to-good relief two weeks after an injection had a 79% chance of still having relief at 12 weeks. However, those who saw poor results at two weeks had a 94% chance of ongoing pain at three months, suggesting the injection either works fairly quickly or not at all. Patients whose PHN had lasted less than about 11 months were more likely to respond.12PubMed Central. Parameters associated with efficacy of epidural steroid injections in the management of postherpetic neuralgia A systematic review rated the evidence for intrathecal (spinal) injections of local anesthetic plus steroid as strong for established PHN, and found that epidural blocks given within two months of shingles onset may reduce the chance of developing PHN in the first place.13Regional Anesthesia & Pain Medicine. Neuraxial and sympathetic blocks in herpes zoster and postherpetic neuralgia: an appraisal of current evidence
Spinal cord stimulation (SCS) is a more advanced technique in which thin electrodes are placed near the spinal cord to deliver electrical pulses that interfere with pain signal transmission. Multiple prospective trials have compared temporary SCS against pulsed radiofrequency (another nerve-targeted procedure) and found that SCS provided better and longer-lasting pain relief, particularly in patients whose pain had moved beyond the acute phase.14PubMed Central. Comparison of the Efficacy and Safety of Temporary Spinal Cord Stimulation versus Pulsed Radiofrequency for Postherpetic Neuralgia15PubMed Central. Short-Term Spinal Cord Stimulation or Pulsed Radiofrequency for Elderly Patients with Postherpetic Neuralgia A separate retrospective study confirmed this pattern, showing that electrical stimulation outperformed radiofrequency for patients in the subacute and chronic stages of herpes zoster pain.16Scientific Reports. Comparative efficacy and safety of pulsed radiofrequency versus spinal cord stimulation in thoracic herpes zoster pain: a retrospective study
A meta-analysis of nerve blocks during the acute shingles phase found that paravertebral blocks and continuous or repeated epidural blocks reduced the incidence of PHN at three months, while single epidural injections and stellate ganglion blocks did not reach significance.17PubMed Central. Effects of applying nerve blocks to prevent postherpetic neuralgia in patients with acute herpes zoster: a systematic review and meta-analysis The takeaway is that timing and technique matter: repeated or continuous blocks appear to work better than one-off injections.
Why PHN Pain Is So Difficult to Control
Understanding why treatment is so often incomplete helps set realistic expectations. During a shingles outbreak, the varicella-zoster virus inflames and physically damages peripheral nerves, the dorsal root ganglia (clusters of nerve cell bodies near the spine), and spinal nerve roots. This damage causes a dramatic loss of nerve endings in the affected skin and lowers the threshold at which nearby nerves fire pain signals, a process called peripheral sensitization.18PubMed Central. Peripheral and central pathogenesis of postherpetic neuralgia
But the damage does not stop at the skin. Ongoing firing from damaged nerve endings triggers changes in the spinal cord itself, where the pain-processing circuits become amplified. This central sensitization explains one of PHN’s most distressing symptoms: allodynia, where a light brush across the skin produces searing pain. In this state, signals from ordinary touch fibers, which normally feel harmless, get interpreted as painful because the spinal cord’s volume knob is turned too high.19PubMed Central. Rethinking the causes of pain in herpes zoster and postherpetic neuralgia: the ectopic pacemaker hypothesis Because PHN involves both peripheral nerve destruction and rewired spinal cord circuitry, no single drug targeting one mechanism can fully silence the pain for most patients. That is why combination therapy, using topical and oral agents that hit different points in the pain pathway, tends to work better than any single drug alone.
Who Develops PHN and Why It Matters for Treatment
Not everyone who gets shingles ends up with PHN, and the risk factors can shape which treatment approach makes sense. The strongest predictor is age: the risk rises steadily after 60, with meta-analyses showing that every additional decade of life meaningfully increases the likelihood.20PubMed Central. A systematic review and meta-analysis of risk factors for postherpetic neuralgia Other independent risk factors include severe rash during the initial shingles episode, the presence of pain before the rash appeared (prodromal pain), and greater severity of acute pain.21PubMed. Risk factors for postherpetic neuralgia in patients with herpes zoster A large meta-analysis also identified smoking, alcohol abuse, immunosuppression, and chronic conditions like diabetes, COPD, hypertension, and kidney disease as independent contributors.22PubMed Central. Risk factors for postherpetic neuralgia: a meta-analysis based on demographic, clinical features, and treatment characteristics
These risk factors matter practically because they influence which treatments are safe. A 70-year-old with kidney disease and diabetes, for example, may need lower doses of gabapentin (which is cleared by the kidneys) and might not tolerate a tricyclic antidepressant due to cardiac risks. Patients with multiple comorbidities and polypharmacy face altered drug metabolism and heightened vulnerability to adverse effects from PHN medications.23PubMed Central. Options for treating postherpetic neuralgia in the medically complicated patient Age-related changes in how the body processes drugs compound the problem, making dose adjustments and careful monitoring essential.24PubMed. Antiepileptics for post-herpetic neuralgia in the elderly: current and future prospects
Non-Drug and Complementary Approaches
Transcutaneous electrical nerve stimulation (TENS) uses low-voltage electrical currents applied through skin electrodes to interfere with pain signals. It is noninvasive, has very few side effects, and avoids drug interactions entirely, which makes it appealing for patients who are already on multiple medications or who have reacted poorly to pharmacotherapy.25PubMed Central. Transcutaneous Electrical Nerve Stimulation for Prevention and Treatment of Post-Herpetic Neuralgia: A Narrative Review A comparative study found that TENS reduced pain scores by roughly 72% in PHN patients, with results comparable to pulsed electromagnetic field therapy.26PubMed Central. A comparative study between transcutaneous electrical nerve stimulation and pulsed electromagnetic field therapy in the management of post-herpetic neuralgia of the sciatic nerve Current guidelines position TENS as an add-on or fallback when medications have not met goals, rather than a standalone first-line therapy.
Acupuncture has also been studied for PHN. A systematic review and meta-analysis concluded that acupuncture may reduce pain intensity and improve quality of life, but the authors emphasized that the existing evidence comes from studies of limited size and methodological quality, and called for larger, more rigorous trials before drawing firm conclusions.27PubMed Central. Is acupuncture an effective postherpetic neuralgia treatment? A systematic review and meta-analysis If you are considering acupuncture, it is reasonable as a complement to conventional treatment rather than a replacement.
One retrospective cohort study comparing pharmacologic and non-pharmacologic management found that medications produced faster and somewhat greater pain relief in the first year, along with better quality-of-life scores. However, the difference in sleep quality between the two approaches narrowed over time and was no longer statistically significant at 12 months.28PubMed Central. Clinical outcomes of pharmacologic versus non-pharmacologic interventions in postherpetic neuralgia: A retrospective cohort study This suggests that non-drug strategies may have their greatest value as part of long-term supportive care rather than for acute pain relief.
Prevention Through Vaccination
The most effective way to avoid treating PHN is to prevent it from developing in the first place. The recombinant zoster vaccine (Shingrix) has largely replaced the older live vaccine and is recommended for adults 50 and older. A systematic review and meta-analysis found that Shingrix substantially reduces the risk of shingles and likely reduces the risk of PHN as well.29PubMed Central. Efficacy and Effectiveness of the Recombinant Zoster Vaccine Against Herpes Zoster, Herpes Zoster Ophthalmicus, Postherpetic Neuralgia and Dementia The vaccine produces a strong immune reaction, so arm soreness, fatigue, and muscle aches after each dose are common, but these short-lived side effects are trivial compared to the months or years of pain PHN can cause.30PubMed Central. Recombinant zoster vaccine (Shingrix®): a new option for the prevention of herpes zoster and postherpetic neuralgia
If you have already had shingles, vaccination can still lower the risk of a future episode. And if shingles does develop, early antiviral treatment (ideally started within 72 hours of the rash) is the other major preventive strategy, though it reduces the severity and duration of the acute episode rather than guaranteeing PHN will not follow.
Botulinum Toxin as an Emerging Option
Botulinum toxin type A, best known for its cosmetic uses, has shown promise for PHN that does not respond to standard treatments. When injected under the skin in the painful area, it appears to block pain signaling through mechanisms beyond simple muscle relaxation, including reducing the release of pain-related neurotransmitters from nerve endings. A review of the evidence concluded that botulinum toxin produced promising and long-lasting results with very few adverse reactions, and suggested it be considered a valid approach particularly for patients who do not respond well to conventional painkillers.31PubMed Central. Botulinum as a Toxin for Treating Post-herpetic Neuralgia The research is still in relatively early stages, and botulinum toxin is not yet part of standard PHN guidelines in most countries, but it represents one of the more interesting directions for patients who have exhausted other options.
The Burden of Living With PHN
It is worth acknowledging that PHN affects far more than just the sensation of pain. Studies in multiple countries have documented that the condition disrupts sleep, erodes quality of life, limits daily activities, and causes significant lost productivity for those still working.32PubMed Central. Patient and economic burdens of postherpetic neuralgia in China33PubMed Central. Economic Burden and Impact on Quality of Life of Herpes Zoster in Spanish Adults Aged 50 Years or Older The constant pain can trigger anxiety and depression, which in turn lower pain thresholds and make existing treatments feel less effective. Addressing sleep, mood, and functional capacity alongside the pain itself tends to produce better overall outcomes than focusing on pain scores alone. If you or someone you care for is dealing with PHN, asking the treating clinician about a comprehensive approach that includes attention to these broader impacts is as important as choosing the right painkiller.